Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$6.99 USD

6.99
415,276

+0.25 (3.71%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $6.99 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

TEM's third-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.

GKOS Stock Declines Despite Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Glaukos' third-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.

CAH Stocks Gains on Q1 Earnings & Sales Beat and Raised '25 EPS View

by Zacks Equity Research

Cardinal Health's first-quarter fiscal 2025 results benefit from solid Pharmaceutical and Specialty Solutions growth. However, OptumRx contract expiry hurts sales.

Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 94.3% upside potential for AngioDynamics (ANGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Avanos Q3 Earnings Meet Estimates, Sales Miss, Gross Margin Contracts

by Zacks Equity Research

Strength in AVNS' Digestive Health segment drives its third-quarter performance

CONMED Beats on Q3 Earnings, Misses on Sales, Lowers '24 Sales View

by Zacks Equity Research

CNMD's Q3 earnings beat estimates on the back of higher revenues and lower costs and expenses.

GE HealthCare Q3 Earnings Beat Estimates, Sales Meet, Net Margin Up

by Zacks Equity Research

GEHC's third-quarter results witness declining segmental revenues in imaging and ultrasound, offset by strong Pharmaceutical Diagnostics performance. The bottom line improves on better pricing.

Debanjana Dey headshot

AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?

by Debanjana Dey

ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.

Inari Medical Q3 Earnings Miss Estimates, Revenues Increase Y/Y

by Zacks Equity Research

NARI's third-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.

TransMedics Stock Falls as Q3 Earnings & Sales Miss Estimates

by Zacks Equity Research

TMDX's third-quarter revenues increase with the utilization of the OCS across all three organs and additional revenues generated by its logistics services. Gross margin contracts.

West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance

by Zacks Equity Research

WST's third-quarter results reflect a recovery in the Proprietary Products segment following elevated customer destocking, hurting sales in the second quarter.

ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE

by Zacks Equity Research

AngioDynamics announces the receipt of CPT Category I code for IRE technology.

Here's Why You Should Retain Inogen Stock in Your Portfolio Now

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for INGN stock.

Intuitive Surgical Q3 Earnings Beat, Procedures Robust

by Zacks Equity Research

ISRG's third-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.

AngioDynamics (ANGO) Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise

by Zacks Equity Research

AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.

Here's Why You Should Add AngioDynamics Stock to Your Portfolio

by Zacks Equity Research

ANGO shows growth potential with its NanoKnife system and expanding U.S. sales but faces challenges from pricing pressure and macroeconomic factors.

AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 26.67% and 1.46%, respectively, for the quarter ended August 2024. Do the numbers hold clues to what lies ahead for the stock?

Here's What Could Help AngioDynamics (ANGO) Maintain Its Recent Price Strength

by Zacks Equity Research

AngioDynamics (ANGO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

New Strong Buy Stocks for September 30th

by Zacks Equity Research

MRX, ANGO, OPRA, ATAT and PAM have been added to the Zacks Rank #1 (Strong Buy) List on September 30, 2024.

ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe

by Zacks Equity Research

AngioDynamics' RECOVER-AV trial evaluates the AlphaVac F1885 System's safety and efficacy in treating acute pulmonary embolism in Europe.

New Strong Buy Stocks for September 13th

by Zacks Equity Research

ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.

New Strong Buy Stocks for September 9th

by Zacks Equity Research

DEC, AFRM, CRNC, ANGO and GIII have been added to the Zacks Rank #1 (Strong Buy) List on September 9, 2024.

AngioDynamics Stock Falls Despite CE Mark for Auryon System

by Zacks Equity Research

ANGO's Auryon Atherectomy System earns CE Mark, which expands its European market reach and enhances PAD treatment with advanced laser technology.

AngioDynamics (ANGO) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

AngioDynamics (ANGO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.